Department of Organic Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran 67149-67346.
Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.
Chem Res Toxicol. 2021 Apr 19;34(4):959-987. doi: 10.1021/acs.chemrestox.0c00483. Epub 2021 Mar 26.
Mechanism-based inactivation (MBI) refers to the metabolic bioactivation of a xenobiotic by cytochrome P450s to a highly reactive intermediate which subsequently binds to the enzyme and leads to the quasi-irreversible or irreversible inhibition. Xenobiotics, mainly drugs with specific functional units, are the major sources of MBI. Two possible consequences of MBI by medicinal compounds are drug-drug interaction and severe toxicity that are observed and highlighted by clinical experiments. Today almost all of these latent functional groups (e.g., thiophene, furan, alkylamines, etc.) are known, and their features and mechanisms of action, owing to the vast experimental and theoretical studies, are determined. In the past decade, molecular modeling techniques, mostly density functional theory, have revealed the most feasible mechanism that a drug undergoes by P450 enzymes to generate a highly reactive intermediate. In this review, we provide a comprehensive and detailed picture of computational advances toward the elucidation of the activation mechanisms of various known groups with MBI activity. To this aim, we briefly describe the computational concepts to carry out and analyze the mechanistic investigations, and then, we summarize the studies on compounds with known inhibition activity including thiophene, furan, alkylamines, terminal acetylene, etc. This study can be reference literature for both theoretical and experimental (bio)chemists in several different fields including rational drug design, the process of toxicity prevention, and the discovery of novel inhibitors and catalysts.
基于机制的失活(MBI)是指细胞色素 P450 将外源化学物代谢生物活化成高反应性中间产物,然后该中间产物与酶结合,导致准不可逆或不可逆的抑制。外源化学物,主要是具有特定功能单元的药物,是 MBI 的主要来源。药物化合物引起的 MBI 的两种可能后果是药物相互作用和严重毒性,这些在临床实验中被观察到并被强调。如今,几乎所有这些潜在的功能基团(如噻吩、呋喃、烷基胺等)都已被知晓,并且由于广泛的实验和理论研究,它们的特征和作用机制已经确定。在过去的十年中,分子建模技术,主要是密度泛函理论,揭示了药物通过 P450 酶产生高反应性中间产物的最可行的机制。在这篇综述中,我们提供了一个全面而详细的图片,展示了计算方法在阐明具有 MBI 活性的各种已知基团的激活机制方面的进展。为此,我们简要描述了进行和分析机制研究的计算概念,然后总结了具有已知抑制活性的化合物的研究,包括噻吩、呋喃、烷基胺、末端乙炔等。这项研究可以为包括合理药物设计、毒性预防过程以及新型抑制剂和催化剂的发现在内的多个不同领域的理论和实验(生物)化学家提供参考文献。